Company / Capital Expenditures
MoonLake Immunotherapeutics Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$35.0K
FY2025
5-year range
$16.0K / $520.0K
FY2021-FY2025
Trend
-93.3%
vs FY2024
Sector context
#181 of 194
Health Care
What the data says
Among 194 Health Care companies, MoonLake Immunotherapeutics is in the bottom 7% for capital expenditures. Declined from $284,000 to $35,000 over the past 2 years.
Based on SEC 10-K filings.
$35,000 in FY2025 with a 3-year CAGR of +29.8%.
Declined from $284,000 to $35,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +29.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 194This company $35.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +29.8%, indicating consistent growth.
- In FY2025, capital expenditures decreased 93.3% year-over-year.
- Ranks #181 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.0K | -93.3% |
| FY2024 | $520.0K | +83.1% |
| FY2023 | $284.0K | +1674.0% |
| FY2022 | $16.0K | -68.4% |
| FY2021 | $50.7K | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026